Continuous manufacturing can reduce cycle times and make drug production more environmentally friendly, but it has yet to replace batch production in any significant way. Chemical & Engineering News revisited the benefits of continuous manufacturing and dug into why it has yet to take off in a feature this week.
Jubilant will use some of the cash to improve its generic drug manufacturing plants in India while also tapping the bank's emerging market healthcare expertise.
Over the past 18 months, India's SeQuent Scientific has won FDA approval of its API plant, sold its specialty chemicals business and acquired a stake in Shasun Pharma. The Bangalore-based business is maintaining the pace and further bolstering its API production business by agreeing to buy Arvee Synthesis.
More growth in its manufacturing operations helped pharma services company WuXi PharmaTech to another strong quarter.
Abbott gets a portfolio of 1,000 new drugs and expects to see its sales in the Latin American market double with its $3 billion buyout out of Chile's CFR Pharmaceutical.
In an effort to control costs, Japan's Daiichi Sankyo is reworking its manufacturing network and says that in Japan, it has even turned over some of its warehousing and logistics to another company.
Software developed by researchers at the University of Pittsburgh and Johns Hopkins University has helped the Republic of Benin in West Africa deliver more vaccines to children most in need, according to a new study.
The U.S. has gotten guilty pleas out of a Texas couple that ran a fake drug wholesaling business that sold nearly $60 million worth of drugs obtained off the street.
Sanofi supply-chain problems have again undermined the French drugmaker's earnings. This time around it is problems with being able to meet vaccine demand in a couple of emerging markets.
Takeda got approval in Japan a month ago for its cell-cultured influenza vaccine it developed with Baxter International. Now, the Japanese drugmaker says the government will pony up another $70 million so it can expand a manufacturing plant for which it has already received significant subsidies.